1 published article · Updated continuously
264 trials tracked for Chronic Hepatitis C: 117 in phase 3 or 4 and 26 with published results. The most-cited published study has 363 citations.
Showing the 50 most-cited and recently-updated of 264 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Several pharmacological interventions have been evaluated for the treatment of Chronic Hepatitis C. Ribavirin demonstrated significant results in early virologic response at week 4 (71.0% to 78.7%; p=0.0353) and sustained virologic response (SVR) at week 72 (33.5% to 49.3%; p<0.0001) 1. While Ribavirin showed a significant reduction in viral load by week 12, the magnitude of log10 reduction was not statistically different between groups 2.
Peginterferon alfa-2a (Pegasys) demonstrated high rates of virological response at the end of treatment (95.2% to 100%) and sustained virologic response (SVR) at 24 weeks post-treatment in some cohorts 8. However, SVR rates varied significantly across different study designs and populations, ranging from 10% to 83% 9 and showing varying success based on genotype 20. One trial reported a 55.6% SVR rate at 24 weeks with Pegasys 21, while another showed lower SVR rates (23.8% to 36.5%) in a different cohort 19.
Other established treatments include Epclusa (SOF/VEL) 4, Sofosbuvir/Velpatasvir [10, 13], Viekira Pak ± ribavirin 11, and ombitasvir, paritaprevir/r, dasabuvir + ribavirin 14. Additionally, TPV/PEG-IFN/RBV showed high SVR12 rates (71% to 100%) 7. Safety data for Raltegravir noted Grade 2 or higher ALT elevations in 24% to 30% of patients 12, while a study on high-dose vitamin C reported changes in serum alanine aminotransferase and interleukin 22 levels 22.
AI synthesis of 13 cited trials, updated Jul 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
